Yvonne Bombard

PhD, BSc

Scientist, Li Ka Shing Knowledge Institute


Dr. Bombard is a genomics health services researcher and Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital. She is an Associate Professor at the University of Toronto in the Institute of Health Policy Management and Evaluation.  Her research focuses on evaluating the adoption of new genomic technologies in clinical practice. She also conducts public and patient engagement research to advance health technology assessment and health service delivery. Dr. Bombard is active in numerous international policy advisory committees; her research informs policy development in this area.  In 2014, Dr. Bombard was the inaugural recipient of the Maurice McGregor Award for Demonstrated Excellence and Leadership Potential from the Canadian Agency for Drugs and Technologies in Health (CADTH) and also received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research in 2011. Recently, she has been awarded a CIHR Foundation grant as an Early Career Investigator, and she holds a CIHR New Investigator Award.

Dr. Bombard holds a Fellowship from Yale University (Health Policy), a Fellowship from the Memorial Sloan-Kettering Cancer Center (Cancer Genomics) and a Fellowship from the University of Toronto (Health Services Research).

Recent Publications

  1. Mighton, C, Shickh, S, Uleryk, E, Pechlivanoglou, P, Bombard, Y. Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis. Genet Med. 2020; :. doi: 10.1038/s41436-020-00957-2. PubMed PMID:32921787 .
  2. Reble, E, Gutierrez Salazar, M, Zakoor, KR, Khalouei, S, Clausen, M, Kodida, R et al.. Beyond medically actionable results: an analytical pipeline for decreasing the burden of returning all clinically significant secondary findings. Hum Genet. 2020; :. doi: 10.1007/s00439-020-02220-9. PubMed PMID:32892247 .
  3. Jiang, S, Anis, AH, Cromwell, I, Mohammadi, T, Schrader, KA, Lucas, J et al.. Health-care practitioners' preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment. Genet Med. 2020; :. doi: 10.1038/s41436-020-0927-x. PubMed PMID:32820245 .
  4. Bombard, Y, Hayeems, RZ. How digital tools can advance quality and equity in genomic medicine. Nat Rev Genet. 2020;21 (9):505-506. doi: 10.1038/s41576-020-0260-x. PubMed PMID:32601319 PubMed Central PMC7322700.
  5. Shickh, S, Gutierrez Salazar, M, Zakoor, KR, Lázaro, C, Gu, J, Goltz, J et al.. Exome and genome sequencing in adults with undiagnosed disease: a prospective cohort study. J Med Genet. 2020; :. doi: 10.1136/jmedgenet-2020-106936. PubMed PMID:32581083 .
  6. Mighton, C, Carlsson, L, Clausen, M, Casalino, S, Shickh, S, McCuaig, L et al.. Quality of life drives patients' preferences for secondary findings from genomic sequencing. Eur J Hum Genet. 2020;28 (9):1178-1186. doi: 10.1038/s41431-020-0640-x. PubMed PMID:32424322 PubMed Central PMC7609335.
  7. Mason, RJ, Searle, KM, Bombard, Y, Rahmadian, A, Chambers, A, Mai, H et al.. Evaluation of the impact of patient involvement in health technology assessments: A scoping review. Int J Technol Assess Health Care. 2020;36 (3):217-223. doi: 10.1017/S0266462320000239. PubMed PMID:32383420 .
  8. Joly, Y, Dalpé, G, Dupras, C, Bévière-Boyer, B, de Paor, A, Dove, ES et al.. Establishing the International Genetic Discrimination Observatory. Nat Genet. 2020;52 (5):466-468. doi: 10.1038/s41588-020-0606-5. PubMed PMID:32203466 .
  9. Bombard, Y, Clausen, M, Shickh, S, Mighton, C, Casalino, S, Kim, THM et al.. Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. Genet Med. 2020;22 (4):727-735. doi: 10.1038/s41436-019-0702-z. PubMed PMID:31822848 PubMed Central PMC7425118.
  10. Joshi, E, Mighton, C, Clausen, M, Casalino, S, Kim, THM, Kowal, C et al.. Primary care provider perspectives on using genomic sequencing in the care of healthy children. Eur J Hum Genet. 2020;28 (5):551-557. doi: 10.1038/s41431-019-0547-6. PubMed PMID:31804631 PubMed Central PMC7171087.
Search PubMed

Affiliations & Other Activities

  • Associate Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
  • Chair, American Society of Human Genetics’ Duty to Recontact Guidelines Workgroup
  • Co-lead, Societal Values and Patient Engagement Program, the Canadian Centre for Applied Research in Cancer Control
  • Member, Ontario Genetics Advisory Committee, Health Quality Ontario
  • Member, Provincial Council for Maternal and Child Health’s Prenatal Screening Advisory Committee
  • Member, Provincial Council for Maternal and Child Health’s Maternal-Child Screening Committee (2016-2017)
  • Member, Steering Committee of the Canadian Coalition for Genetic Fairness
  • Visiting Investigator, Memorial Sloan Kettering Cancer Center, Clinical Genetics Service (2013-2016)
  • Chair, American Society of Human Genetics’ Social Issues Committee (2014-2015, 2017-2018)
  • Chair, European Huntington Disease Network’s Discrimination Working Group (2009-2010)
  • Member, Cancer Quality Council of Ontario’s Personalized Medicine Steering Committee (2010-2011)
  • Member, Cancer Care Ontario’s Patient Experience and Performance Committee (2013-2015)
  • Member, Patient and Citizen Involvement Working Group, Health Technology Assessment International
  • Member, Ethics Working Group, Health Technology Assessment International